B1B3 [464 B1B3]細(xì)胞
ATCC Number： CRL-2249?
是否是腫瘤細(xì)胞： 0
物種來(lái)源： 小鼠
數(shù)量： 大量
生長(zhǎng)狀態(tài)： 懸浮生長(zhǎng)
運(yùn)輸方式： 凍存運(yùn)輸
細(xì)胞形態(tài)： **樣
**類型： IgG1
Designations: B1B3 [464 B1B3]
Depositors: G Schonfeld
Isotype: IgG1
Biosafety Level: 1
Shipped: frozen
B1B3 [464 B1B3]細(xì)胞Medium & Serum: See Propagation
Growth Properties: suspension
Organism: Mus musculus (B cell); Mus musculus (myeloma) deposited as mouse (B cell); mouse (myeloma)
Morphology: lymphoblast
Source: Cell Type: hybridoma: B lymphocyte;
Cellular Products: immunoglobulin; monoclonal antibody; against human low density lipoprotein
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Tumorigenic: Yes
Comments: Animals were immunized with human low density lipoprotein (LDL) obtained from plasma from a donor with familial hypercholesterolemia.
Spleen cells were fused with Sp2/0-Ag14 myeloma cells.
The antibody binds to an epitope in amino acids 3506 through 3635 on human apolipoprotein B.
It cross competes with antibody B1B6 (see ATCC CRL-2248).
The antibody blocks binding of LDL to LDL receptors.
B1B3 [464 B1B3]細(xì)胞It does not bind apolipoprotein B48.
Propagation: ATCC complete growth medium: Dulbecco's modified Eagle's medium with 4.5 g/L glucose, 0.1 mM non-essential amino acids and 1 mM sodium pyruvate, 85%; horse serum, 10%; fetal bovine serum, 5%
Subculturing: Medium Renewal: Every 2 to 3 days
Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml.
Preservation: Culture medium, 95%; DMSO, 5%
References: 22498: Krul ES, et al. Roles of apolipoproteins B and E in the cellular binding of very low density lipoproteins. J. Clin. Invest. 75: 361-369, 1985. PubMed: 3973009
22505: Hahm KS, et al. B1B3 [464 B1B3]細(xì)胞Limited proteolysis selectively destroys epitopes on apolipoprotein B in low density lipoproteins. J. Lipid Res. 24: 877-885, 1983. PubMed: 6195279
22506: Krul ES, et al. Regional specificities of monoclonal anti-human apolipoprotein B antibodies. J. Lipid Res. 29: 937-947, 1988. PubMed: 2457642
22508: Kinoshita M, et al. Modification of the core lipids of low density lipoproteins produces selective alterations in the expression of apoB-100 epitopes. J. Lipid Res. 31: 701-708, 1990. PubMed: 1693649
22733: Tikkanen MJ, et al. Expression of apolipoprotein B epitopes in very low density lipoprotein subfractions. Studies with monoclonal antibodies. Arteriosclerosis 4: 138-146, 1984. PubMed: 6200098
22734: Krul ES, et al. B1B3 [464 B1B3]細(xì)胞Two distinct truncated apolipoprotein B species in a kindred with hypobetalipoproteinemia. Arteriosclerosis 9: 856-868, 1989. PubMed: 2574033
23204: Tikkanen NJ, et al. Antigenic mapping of human low density lipoprotein with monoclonal antibodies. J. Lipid Res. 23: 1032-1038, 1982. PubMed: 6183385
23205: Tikkanen MJ, et al. Differential reactivity of human low density lipoproteins with monoclonal antibodies. J. Lipid Res. 24: 1494-1499, 1983. PubMed: 6197500
23206: Krul ES, et al. Heterogeneity of apolipoprotein E epitope expression on human lipoproteins: importance for apolipoprotein E function. J. Lipid Res. 29: 1309-1325, 1988. PubMed: 2466929
